Type B - Core Scientific, Inc. (CORZ) 20261031 Stock Analysis

📅 Core Scientific Key Upcoming Events

• November 05, 2026 Q3 2026 Earnings Release (Confirmed)
  • Description: Core Scientific will publish its third-quarter results before the U.S. market opens, followed by an 8:30 a.m. ET conference call. Investors will focus on newly activated colocation capacity, contracted customer revenue, capital expenditures, funding requirements, and progress toward positive recurring operating cash generation.
• 2027 Expansion of AMD-Backed High-Density Colocation Capacity (Estimated)
  • Description: The company is expected to advance site development and energization under its AMD infrastructure partnership. Individual commissioning dates remain dependent on construction, utility readiness, and customer acceptance, so the timing represents an execution window rather than an officially fixed completion date.

🏢 Step 1: Core Scientific Company Overview & Business Model

Q1-A1. What is Core Scientific?

• Company Name (Ticker): Core Scientific, Inc. (CORZ)
• Sector: Technology
• Exchange: NASDAQ
• Founded: 2017
• Listing Date: January 20, 2022 (original public listing; current post-restructuring common shares began trading in January 2024)
• Fiscal Year End: December
• Headquarters: United States, Dover, Delaware (registered office; operational management in Miami, Florida)
• CEO: Adam Sullivan (Founder status: No)
• Market Cap: $4.26B
• Shares Outstanding: 321.34M
• Current Price: $13.25
• Annual Dividend Yield: ➖ Not applicable
• Ex-dividend Date: ➖ Not applicable
• As-of: October 31, 2026 (ET)

Q1-A2. How Does Core Scientific Make Money?

• High-Density Data Center Colocation Revenue: Core Scientific develops and operates data-center infrastructure providing contracted power, cooling, physical space, security, and facility management to customers running intensive computing workloads, particularly artificial intelligence.
• Long-Term Infrastructure Contracts: Customers commit to dedicated capacity under multiyear arrangements, allowing Core Scientific to earn recurring infrastructure-service revenue as sites become operational and billable.
• Digital Asset Mining Revenue: The company also earns Bitcoin mining rewards through proprietary mining operations and fees for hosting third-party mining equipment. This is increasingly a legacy business as capital and electrical capacity are redirected toward AI colocation.
• Economic Engine: The central investment opportunity is converting scarce, utility-connected electrical capacity into long-duration contracted revenue while controlling construction costs, debt financing, and maintenance expenditure.

Q1-A3. Core Scientific’s Revenue Segments & Core Income Sources

• Q2 2026 Revenue: Total reported revenue was $164.20M, an increase of approximately 108.8% YoY from $78.63M.
  • Colocation: $136.67M, representing 83.2% of quarterly revenue, compared with $10.56M one year earlier.
  • Digital Asset Self-Mining: $21.54M, representing 13.1%, compared with $62.42M one year earlier.
  • Digital Asset Hosted Mining: $6.00M, representing 3.7%, compared with $5.64M one year earlier.
• Primary Growth Driver: Colocation revenue increased approximately 1,194% YoY, reflecting accelerated commissioning and billing of high-density computing capacity.
• Business Mix Transformation: Colocation expanded from approximately 13.4% of Q2 2025 revenue to 83.2% in Q2 2026. This is a fundamental shift from cryptocurrency-price-sensitive mining economics toward contracted data-center infrastructure.
• Contracted Capacity: By the July 2026 results announcement, total leased customer power capacity reached approximately 1.1 GW, associated with more than $24B of potential contracted revenue over relevant contract lives. This represents potential cumulative contractual revenue, not current annual sales or guaranteed free cash flow.

Q1-A4. Who Are Core Scientific’s Competitors?

• Direct Infrastructure Competitors: Applied Digital, TeraWulf, Cipher Digital, IREN, and other developers converting energy-intensive facilities into AI-ready data centers compete for power availability, financing, construction capacity, and hyperscale customers.
• Established Data Center Operators: Equinix and Digital Realty possess operating experience, established enterprise relationships, and more diversified infrastructure portfolios, although their customer mix and facility economics differ.
• Competitive Advantage: Core Scientific controls an expanding portfolio of power-connected sites and has demonstrated its ability to activate substantial high-density capacity for large customers.
• Competitive Weakness: Data-center construction is highly capital-intensive. Core Scientific does not possess an exclusive technology platform or network effect preventing adequately funded competitors from developing similar facilities.
• Strategic Position: The company is an early large-scale converter of cryptocurrency-mining infrastructure into AI colocation capacity, but not the original inventor of high-density data-center infrastructure.
• Legacy Displacement: Traditional Bitcoin-mining facilities and less capable power-intensive hosting sites may lose economic competitiveness as premium electrical capacity shifts toward AI computing customers.

Q1-A5. What Problem Does Core Scientific Solve?

• Power Availability Bottleneck: AI infrastructure developers often face extended utility interconnection, permitting, and site-construction timelines that delay deployment of expensive computing equipment.
• Infrastructure Delivery Solution: Core Scientific offers access to developed or developable electrical infrastructure combined with high-density cooling, facility operations, and physical security.
• Customer Value Proposition: Customers can deploy AI computing capacity without independently assembling every component of the underlying powered facility.
• Economic Benefit: Reliable capacity delivered earlier can accelerate customer revenue generation and improve utilization of computing hardware.
• Primary Constraint: The benefit depends on Core Scientific delivering operational capacity within agreed schedules and budgets; a signed lease alone does not establish economic profitability.

Q1-A6. Core Scientific Key Milestones: Past 12 Months

• October 30, 2025 Termination of the CoreWeave Merger Agreement
  • Description: Shareholders did not approve the proposed approximately $9B all-stock acquisition. The merger agreement was terminated, and Core Scientific remained an independently listed Nasdaq company under CORZ. Its commercial relationship with CoreWeave continued.
• May 06, 2026 Q1 2026 Earnings Release
  • Description: Total revenue reached $115.24M, including $77.54M of colocation revenue. The quarter demonstrated growing commercial conversion of contracted data-center capacity.
• July 28, 2026 AMD Infrastructure Partnership Announcement
  • Description: Core Scientific announced an infrastructure partnership with AMD involving approximately 530 MW of initial contracted capacity across five sites under 15-year agreements, with more than $14B of potential base contracted revenue. The broader partnership contemplated the possibility of up to 2.5 GW of leasable capacity.
• July 28, 2026 Q2 2026 Earnings Release
  • Description: Quarterly revenue increased to $164.20M, colocation revenue reached $136.67M, and adjusted EBITDA reached $41.1M. Quarterly capital expenditures of approximately $797.5M highlighted the substantial funding required to execute the expansion strategy.
• August 14, 2026 Completed Acquisition of Polaris DS
  • Description: The acquisition advanced Core Scientific’s planned Muskogee development toward approximately 1.5 GW of gross power capacity, adding expansion optionality while increasing development complexity.
• August 27, 2026 Secured $600M of Senior Secured Credit Facilities
  • Description: Additional financing strengthened the company’s ability to fund capital-intensive development, although secured borrowing increases financial obligations and reduces future funding flexibility.
• September 25, 2026 Appointment of Jay Elms as Chief Commercial Officer
  • Description: The appointment strengthened commercial leadership as the company expanded its high-density colocation customer pipeline beyond its earlier mining-oriented business.

Q1-A7. Step 1 Key Takeaways

• Step 1 Summary: Core Scientific has transformed into a high-density data-center infrastructure developer, with colocation representing more than 80% of recent quarterly revenue. Its contracted power capacity creates substantial growth potential, but execution speed, financing costs, and customer concentration are central to the investment case.

🌲 Step 2: Core Scientific’s Economic Moat, Market Size & Scalability

Q2-A1. Does Core Scientific Have a Durable Economic Moat?

• Electrical Infrastructure Access: Utility-connected sites with substantial usable power capacity are increasingly valuable because new interconnections and transmission upgrades can require multiyear development.
• Execution Experience: Existing data-center operations, large-scale electrical infrastructure, and demonstrated customer billing provide practical experience that inexperienced entrants may lack.
• Switching Costs: Moving extensive high-density computing installations between facilities can involve substantial logistics, downtime, equipment reconfiguration, and contractual penalties.
• Technology Exclusivity: Core Scientific’s physical infrastructure is differentiated by location, power availability, and execution rather than exclusive intellectual property.
• Network Effects: No meaningful software-style network effect has been established. Additional customers do not automatically increase the utility of the service for existing customers.
• Pricing Power: Scarce powered capacity can support favorable contract negotiations, but hyperscale customers have substantial bargaining power, and long-duration contracts can constrain future repricing.

Q2-A2. How Big Is Core Scientific’s Market? (TAM)

• Total Addressable Market: The relevant market is high-density colocation infrastructure supporting AI training, inference, and other power-intensive computing workloads, rather than the total global value of AI software or semiconductor spending.
• Market Growth Outlook: Structural demand for computing power supports a multiyear expansion opportunity, although a single independently comparable market revenue estimate and CAGR cannot be established from the reviewed evidence.
• Serviceable Addressable Market: Core Scientific’s practical opportunity is bounded by available electrical power, facility specifications, geography, construction schedules, and creditworthy customer demand.
• Serviceable Obtainable Market: The company’s approximately 1.1 GW of leased customer power capacity provides a more economically meaningful indication of its near-term commercial opportunity than broad AI market forecasts.
• Market Opportunity Assessment: The potential to convert additional gigawatts of power into billable capacity is material, but theoretical capacity and multiyear contract totals must not be confused with current annualized revenue.

Q2-A3. How Real Is Core Scientific’s TAM? (Quality Check)

• Willingness to Pay: Advanced computing customers can pay substantial recurring fees for reliable power delivery and high-density facilities because delays can leave expensive computing equipment idle.
• Market Structure: The market is competitive rather than winner-takes-all. Different geographic locations, power grids, and customer requirements can support multiple profitable operators.
• Contract Quality: Long-term agreements improve revenue visibility, but customers’ creditworthiness, contract protections, and commissioning conditions determine realized value.
• Capital Intensity: High facility construction costs, electrical infrastructure spending, and financing requirements reduce the share of contracted revenue that eventually becomes distributable cash.
• Entry Barriers: Power interconnections, permitting, site development, technical expertise, and construction coordination create meaningful practical barriers.

Q2-A4. Can Core Scientific Keep Expanding Its Market?

• Penetration Rate: The proportion of the overall AI colocation market captured by Core Scientific cannot be reliably measured from the available market-denominator evidence. Its leased capacity nevertheless indicates an established commercial footprint.
• Physical Scalability: Existing sites and expansion opportunities provide a meaningful capacity pipeline, including the Muskogee development.
• Revenue Scalability: Once a facility becomes operational, incremental contracted revenue can generate attractive contribution margins against an established infrastructure cost base.
• Marginal Cost: Expansion is not a near-zero-cost software model. Each additional site requires construction, electrical equipment, cooling systems, capital, and ongoing maintenance.
• Expansion Bottlenecks: Funding availability, utility energization, customer acceptance, and specialized construction resources determine how quickly new capacity becomes billable.

Q2-A5. Step 2 Key Takeaways

• Scoring Rationale:
  • Economic Moat (6/10): Scarce electrical capacity and switching costs provide meaningful differentiation, but technology exclusivity and network effects are limited.
  • Market Size (5/5): The combination of demonstrated customer demand and contracted gigawatt-scale capacity establishes a substantial addressable growth opportunity.
  • Market Quality·Profitability (6/7): Long-term contracted infrastructure services offer attractive revenue visibility, tempered by capital intensity and concentrated buyers.
  • Market Penetration·Scalability (8/8): Existing power-connected assets, approximately 1.1 GW of leased capacity, and additional development opportunities support significant physical expansion.
• 📊 Step 2 Score: 25/30 pts (Economic Moat 6/10 + Market Size 5/5 + Market Quality·Profitability 6/7 + Market Penetration·Scalability 8/8)
• Step 2 Summary: Core Scientific possesses commercially valuable electrical infrastructure and substantial contracted growth opportunities. Its principal limitation is that expansion requires very large amounts of additional capital rather than benefiting from software-like marginal economics.

🚀 Step 3: How Fast Is Core Scientific Growing? Hyper-Growth Metrics

Q3-A1. How Fast Is Core Scientific Growing? (Revenue Trajectory)

• Quarterly Revenue Acceleration: Q2 2026 revenue reached $164.20M, up 108.8% YoY from $78.63M and 42.5% QoQ from $115.24M in Q1 2026. Q1 2026 revenue had increased approximately 45% from the comparable prior-year quarter, indicating accelerating consolidated growth.
• Colocation Growth Dominates: Colocation revenue increased from $77.54M in Q1 2026 to $136.67M in Q2 2026, representing approximately 76.3% QoQ growth.
• Historical Revenue Context: FY2025 revenue declined approximately 37.5% to $319.02M from $510.67M in FY2024 because the company was transitioning away from Bitcoin mining. The recent reacceleration therefore represents a business-mix transformation rather than uninterrupted organic growth in a stable product category.
• J-Curve Assessment: Core Scientific is in the steep revenue-activation stage of an infrastructure expansion cycle. Sustained acceleration depends on scheduled megawatts becoming billable, not merely securing additional contractual commitments.

Q3-A2. Core Scientific’s Key Growth Metrics

• Selected Growth Indicators: Billing megawatts, leased customer power capacity, and colocation revenue per billing megawatt best capture commercialization of Core Scientific’s physical infrastructure.
  • Billing Megawatts: Billing capacity increased from approximately 225 MW in Q1 2026 to 395 MW in Q2 2026, representing a 75.6% sequential increase.
  • Leased Customer Capacity: Approximately 1.1 GW of leased customer power capacity demonstrates a substantial development pipeline extending beyond the currently billable base.
  • Annualized Colocation Revenue: By mid-July 2026, 437 MW of billable capacity represented approximately $635M of average annualized GAAP colocation revenue, equivalent to roughly $1.45M per billing MW annually on that snapshot basis.
• Growth Conversion Gap: Leased capacity and billing capacity represent different stages of development; the approximately 1.1 GW of contracted power should not be multiplied mechanically by current unit revenue without accounting for commissioning schedules, customer-specific pricing, and contract structure.

Q3-A3. Are Core Scientific’s Unit Economics Improving?

• Gross Margin Improvement: Consolidated gross margin expanded from approximately 6.4% in Q2 2025 to 42.7% in Q2 2026, supported by the transition toward higher-margin colocation revenue.
• Colocation Contribution: Q2 2026 colocation revenue of $136.67M against direct segment costs of $56.69M produced approximately 58.5% segment gross margin before corporate overhead and other operating expenses.
• Adjusted EBITDA: Q2 2026 adjusted EBITDA reached $41.1M, compared with $8.9M in Q1 2026, indicating improving earnings contribution from operating infrastructure.
• Rule of 40: Using approximately 26.4% TTM revenue growth and a negative 217.5% TTM conventional FCF margin produces roughly -191.1%, far below the 40% benchmark. For a major construction-phase infrastructure developer, this is a capital-intensity warning rather than a directly comparable SaaS efficiency measure.
• LTV/CAC: Not applicable as a standard subscription-customer acquisition metric. Contract economics, construction cost per MW, and contracted returns on invested infrastructure are more appropriate.
• Unit Economics Conclusion: Gross profit per operating facility is improving materially, but profitability must ultimately be evaluated after depreciation, financing costs, and the substantial investment required to activate new sites.

Q3-A4. Step 3 Key Takeaways

• Scoring Rationale:
  • Revenue Growth Acceleration (9/12): Consolidated revenue growth accelerated sharply as colocation became dominant, although mining runoff and capacity commissioning create an uneven comparison base.
  • Sector-Specific Growth Metrics (9/10): Billing MW, contracted capacity, and colocation revenue growth provide strong evidence of commercial execution.
  • Unit Economics·Margin (4/8): Gross margins and adjusted EBITDA improved significantly, but negative operating earnings and deeply negative conventional FCF limit demonstrated economic returns.
• 📊 Step 3 Score: 22/30 pts (Revenue Growth Acceleration 9/12 + Sector-Specific Growth Metrics 9/10 + Unit Economics·Margin 4/8)
• Step 3 Summary: Core Scientific’s colocation revenue acceleration is substantial and supported by actual customer billing. However, improved facility-level economics have not yet translated into sustainable company-wide profitability or positive post-construction free cash flow.

💪 Step 4: Core Scientific’s Profit Potential & Free Cash Flow

Q4-A1. Can Core Scientific Turn Growth Into Profit?

• Operating Loss: Q2 2026 GAAP operating loss was approximately $78.47M, compared with $26.28M in Q2 2025, despite strong revenue and gross-profit growth.
• Nonrecurring and Transition Costs: The quarter included approximately $41.95M of contract termination losses, $19.50M of asset remeasurement losses, and $27.04M of colocation organizational and startup costs.
• Net Income Distortion: The Q2 2026 GAAP net loss of approximately $1.16B was dominated by a $1.05B fair-value loss on warrants and contingent value rights. This noncash item makes GAAP net income a poor standalone measure of current facility performance.
• Operating Leverage Evidence: Adjusted EBITDA improved from $8.9M in Q1 2026 to $41.1M in Q2 2026, demonstrating emerging operating leverage even though GAAP profitability remains unproven.
• Break-Even Outlook: Sustained profitability requires additional contracted capacity to enter service, startup costs to moderate, and recurring gross profit to cover depreciation, corporate expenses, and financing costs.

Q4-A2. Does Core Scientific Generate Free Cash Flow?

• Operating Cash Flow: TTM operating cash flow through June 2026 was approximately $520.24M, compared with $278.25M in FY2025. This improvement was materially influenced by working-capital movements, including customer-related deferred revenue.
• Capital Expenditures: TTM capital expenditures reached approximately $1.48B, compared with $729M in FY2025, reflecting rapid construction and facility development.
• Free Cash Flow: Conventional TTM FCF, calculated as operating cash flow less capital expenditures, was approximately -$957.75M, compared with -$450.75M in FY2025.
• Self-Funding Assessment: Operating cash generation does not presently cover total development spending. External financing and customer-related funding arrangements remain important to the expansion plan.
• Capital Efficiency: The decisive future measure is the recurring cash yield on completed facilities relative to their total construction and financing costs, not merely reported adjusted EBITDA during construction.

Q4-A3. Step 4 Key Takeaways

• Scoring Rationale:
  • Operating Leverage·Path to Profit (5/8): Rapid gross-profit and adjusted EBITDA improvement supports a plausible path toward recurring profitability, but GAAP operating losses remain substantial.
  • FCF·Capital Efficiency (2/7): Approximately $958M of negative TTM conventional FCF shows that the current expansion program materially exceeds internally generated cash.
• 📊 Step 4 Score: 7/15 pts (Operating Leverage·Path to Profit 5/8 + FCF·Capital Efficiency 2/7)
• Step 4 Summary: Core Scientific is developing an increasingly profitable colocation operating base, but substantial capital spending keeps consolidated cash generation deeply negative. Achieving self-funded growth remains a major unfinished milestone.

👔 Step 5: Core Scientific Management & Shareholder Alignment

Q5-A1. Who Leads Core Scientific? (Founder & Management)

• CEO Leadership: Adam Sullivan leads the company’s transition from Bitcoin mining toward AI-focused high-density colocation infrastructure. He is not the original founder of the company.
• Strategic Execution: Management has demonstrated meaningful commercial progress by increasing billing capacity to 395 MW in Q2 2026 and expanding leased customer capacity to approximately 1.1 GW.
• Capital Strategy: The team has pursued large customer agreements, infrastructure acquisitions, and secured financing to accelerate development.
• Guidance Credibility: Revenue and billing-capacity progress provide tangible evidence of execution, although a comprehensive historical record of meeting construction budgets and long-term return targets is not yet established.
• Management Challenge: The company’s operating success increasingly depends on disciplined financing, project delivery, and balancing long-term lease economics against near-term funding demands.

Q5-A2. Is Core Scientific’s Management Aligned With Shareholders?

• Management Ownership: CEO Adam Sullivan held approximately 4.39M shares following an October 16, 2026 tax-withholding transaction, providing meaningful exposure to the company’s equity value.
• Open-Market Insider Purchases: Director Eric Stanton Weiss purchased 7,000 shares on August 18, 2026 at approximately $19.19 and another 6,000 shares on September 15 at approximately $16.33. Director Elizabeth Crain purchased 6,000 shares on August 20 at approximately $18.33.
• Insider Sales: Todd M. Duchene reported recurring sales of approximately 10,000 shares per transaction during several weeks in September and October 2026, including October 26. These transactions were associated with scheduled trading arrangements and should not automatically be interpreted as discretionary bearish signals.
• CEO Equity Withholding: Sullivan’s October 16 disposition of 21,839 shares was coded as a tax-withholding transaction, not an ordinary open-market investment sale.
• Net Insider Direction: Recent disclosed open-market activity included approximately 19,000 purchased shares by the identified directors, alongside substantially greater recurring scheduled sales by Duchene. A complete trailing-12-month aggregate across all insiders was not established.
• Compensation Alignment: Equity ownership creates financial incentives for share-price appreciation, but the economic quality of compensation depends on dilution, vesting structures, and whether incentives reward returns on capital rather than capacity expansion alone.
• Governance Assessment: The rejected CoreWeave acquisition demonstrates that shareholder voting can materially influence strategic outcomes, although it also exposed disagreements concerning transaction valuation and governance.

Q5-A3. Step 5 Key Takeaways

• Scoring Rationale:
  • Founder Management·Vision (5/8): The non-founder management team has executed a credible infrastructure transformation but has not yet established consistent full-cycle profitability.
  • Alignment·Accountability (6/7): Meaningful CEO ownership, disclosed director purchases, and demonstrated shareholder influence support alignment, partially offset by scheduled insider sales and equity-compensation considerations.
• 📊 Step 5 Score: 11/15 pts (Founder Management·Vision 5/8 + Alignment·Accountability 6/7)
• Step 5 Summary: Management has delivered substantial commercial progress, and insider ownership supports alignment. The next test is whether aggressive capacity expansion produces durable returns on equity after financing and dilution.

⛵ Step 6: Core Scientific Market Flow & Sentiment

Q6-A1. Analyst Consensus vs Core Scientific Guidance

• Revenue Expectations: Compiled FY2026 revenue consensus was approximately $675.64M, representing approximately 111.8% growth from FY2025 revenue of $319.02M.
• Operating Expectations: The compiled forecast included approximately -$307.18M of operating income and -$3.79 in EPS, indicating that investors were still anticipating accounting losses during the expansion phase.
• Guidance Comparison: Management’s disclosed capacity, contracted revenue, and billing statistics do not constitute a directly comparable full-year GAAP revenue and EPS guidance midpoint. An exact company-guidance-versus-consensus percentage gap therefore cannot be established.
• Analyst Sentiment: The compiled analyst recommendation distribution remained heavily positive, but bullish price targets depend on successful monetization of contracted capacity and effective financing.
• Estimate Risk: The market may react sharply to revisions in the schedule for billable megawatts, capital expenditures, interest expense, or customer acceptance.

Q6-A2. What Is Core Scientific’s Short Interest?

• Institutional Ownership: Reported institutional holdings represented approximately 110.0% of shares outstanding on an aggregated reporting basis. This figure can exceed 100% because of reporting dates, securities lending, and overlapping ownership calculations; it should not be interpreted as a precise count of uniquely held shares.
• Public Float: Approximately 276.18M shares were classified as floating shares.
• Short Interest: A current, consistently dated percentage of public float sold short could not be established from the available evidence.
• Days-to-Cover: A matching short-interest settlement figure and average-volume denominator were unavailable, preventing a defensible current days-to-cover estimate.
• Market Sentiment: Heavy institutional participation and pronounced volatility create the potential for substantial position adjustments, but a short squeeze cannot be established from ownership data alone.

Q6-A3. Step 6 Key Takeaways

• Scoring Rationale:
  • Consensus vs Guidance (2/3): Revenue forecasts anticipate rapid expansion, while actual colocation billing growth supports the operating narrative; exact guidance comparability remains limited.
  • Supply·Short Interest (1/2): Institutional participation is substantial, but verified short-interest and days-to-cover figures are insufficient for a stronger directional conclusion.
• 📊 Step 6 Score: 3/5 pts (Consensus vs Guidance 2/3 + Supply·Short Interest 1/2)
• Step 6 Summary: Analyst sentiment is generally bullish on long-term colocation growth, but the stock remains exposed to expectation changes around project delivery, financing, and quarterly results.

🧨 Step 7: Core Scientific Catalysts & Price Triggers

Q7-A1. What Could Re-Rate Core Scientific Stock? (Next 12 Months)

• 1 Additional Billable Capacity From Existing Contracts
  • Timing: Q4 2026 through 2027.
  • Success Conditions: Core Scientific energizes additional facilities on schedule, increases billable MW, and converts contracted capacity into recurring colocation revenue.
  • Failure Risk: Utility delays, construction overruns, or customer acceptance problems postpone revenue generation while financing costs continue.
• 2 AMD Infrastructure Partnership Execution
  • Timing: 2027 development and commissioning milestones.
  • Success Conditions: Initial contracted capacity progresses through permitting, site preparation, electrical infrastructure installation, and customer deployment.
  • Failure Risk: Development delays or unexpected costs reduce project returns and postpone anticipated contracted revenue.
• 3 Improvement in Recurring Operating Profitability
  • Timing: Quarterly financial releases over the next 6-12 months.
  • Success Conditions: Colocation gross profit and adjusted EBITDA increase faster than recurring operating costs, while capital spending becomes more predictable.
  • Failure Risk: Financing expense, depreciation, and construction-related expenditure prevent operating improvements from translating into positive shareholder cash flow.

Q7-A2. Core Scientific’s Estimate Revision Trend

• Revenue Estimate Direction: FY2026 compiled revenue expectations of approximately $675.64M imply growth materially faster than the historical mining business. A consistent sequence of consensus observations across the preceding 90 days was not available to quantify the revision rate.
• Operating Estimate Direction: FY2026 operating losses and negative EPS expectations reflect the continued cost of the infrastructure transition.
• Revision Sensitivity: Quarterly changes in billable power capacity and contracted revenue activation are likely to be more informative than short-term GAAP EPS volatility caused by warrant remeasurement.
• Assessment: The operational evidence supports a growth-oriented outlook, but a verified upward revision streak is not established.

Q7-A3. Step 7 Key Takeaways

• Scoring Rationale:
  • Catalyst Strength (3/3): Large contracted colocation projects and identifiable capacity-activation milestones provide meaningful potential revaluation catalysts.
  • Estimated Trend (1/2): Strong operating growth supports the forward revenue case, although a quantified, sustained upward consensus revision trend is not established.
• 📊 Step 7 Score: 4/5 pts (Catalyst Strength 3/3 + Estimated Trend 1/2)
• Step 7 Summary: Core Scientific possesses significant operational catalysts, especially capacity activation and improved recurring margins. The central challenge is converting those achievements into economic returns after financing and construction costs.

⚖️ Step 8: Is Core Scientific Fairly Valued? Valuation Analysis

Q8-A1. Core Scientific’s Key Valuation Multiples

• PS Ratio: 9.67x (overvalued) — The equity valuation remains demanding relative to the current TTM revenue base, even allowing for rapid contracted capacity activation.
• P/FCF Ratio: N/A (not applicable) — Conventional TTM FCF is negative during major construction.
• P/OCF Ratio: 8.18x (fairly valued) — The positive operating cash-flow denominator is materially influenced by customer-related working capital and is not equivalent to recurring distributable cash.
• EV/Sales Ratio: 15.66x (overvalued) — Significant debt increases enterprise value relative to recognized revenue.
• EV/EBITDA Ratio: N/A (not applicable) — The standardized trailing denominator is not sufficiently representative of the emerging contracted colocation business.
• EV/FCF Ratio: N/A (not applicable) — Negative conventional FCF prevents a meaningful positive cash-flow multiple.
• Forward PE: N/A (not applicable) — Forward earnings remain negative.
• PEG Ratio: N/A (not applicable) — Negative earnings make conventional earnings-growth valuation unsuitable.
• Scoring Rationale: Core Scientific’s current enterprise valuation capitalizes substantial future facility activation, while recognized revenue and post-construction cash flow remain relatively immature. Positive operating cash flow does not eliminate the economic cost of constructing capacity.
• 📌 (1) Axis Q8-A1 Score: -3

Q8-A2. Core Scientific vs Peers: Valuation Comparison

• Multiple selection based on peer comparison: EV/Sales is the preferred diagnostic because several developing AI infrastructure operators have negative GAAP earnings and materially different financing structures.
• Calculation of peer-to-peer deviation rate: N/A — a sufficiently reconciled current arithmetic peer mean could not be established across comparable leased-capacity, revenue-recognition, financing, and development-stage definitions.
  • 🧮 Calculation Formula: ((Core Scientific EV/Sales 15.66x - verified comparable peer mean unavailable) / verified comparable peer mean unavailable) × 100 = N/A.
• Scoring Rationale: Applied Digital, TeraWulf, and IREN provide relevant competitive reference points, but differences in mining exposure, GPU services, contracted colocation, and capital structure make an unadjusted numerical mean misleading. No verified peer deviation is assigned.
• 📌 (2) Axis Q8-A2 Score: 0

Q8-A3. What Is Core Scientific Worth in the Future? (Forward Valuation)

• Implied Future Multiple: A reliable 2028 normalized revenue or operating-profit forecast with matched financing, dilution, and discount assumptions could not be established. Accordingly, an undiscounted current-enterprise-value-to-future-revenue ratio would not provide a defensible future-date valuation.
• Scoring Rationale: The company is undergoing a major transition in capacity, customer mix, debt financing, and capital requirements. A two-to-three-year future-value estimate requires a sufficiently supported forecast of billable megawatts, project margins, and capital funding, which is not available on a consistently comparable basis.
• 📌 (3) Axis Q8-A3 Score: ➖

Q8-A3-1. What Growth Hurdle Does the Market Demand From Core Scientific? (Forward Valuation Alternative)

• Scoring Rationale: At approximately 9.67x TTM sales and 15.66x enterprise value to TTM sales, the market requires substantial growth in recognized colocation revenue and improvement in recurring profitability to justify the present valuation. Existing contracts provide a credible growth pathway, but the large construction budget and financing burden make the required operational conversion demanding rather than automatic.
• 📌 (3) Axis Q8-A3-1 Score: -2

Q8-A4. Final Valuation Adjustment

• Scoring Rationale: Core Scientific’s transition from Bitcoin mining to contracted AI infrastructure materially changes the relevant valuation framework, but its improved revenue visibility and significant funding obligations are already considered in the absolute valuation and forward-growth assessment. No additional independent adjustment is warranted.
• 📌 (4) Axis Q8-A4 Score: 0

Q8-A5. Valuation Adjustment Score Calculation

• Calculation Process:
  • (1) Axis (Key Valuation Indicator): -3 pts (Overvalued)
  • (2) Axis (Peer-to-peer deviation rate): 0 pts (Comparable peer deviation unavailable)
  • (3) Axis (Justification of Growth): -2 pts (Substantial growth and margin realization required)
  • (4) Axis (Final adjustment): 0 pts (No additional independent valuation adjustment)
• 📊 Valuation Adjustment Score: A1 (-3) + A2 (0) + A3 (-2) + A4 (0) = -5 pts
• Commentary: The valuation recognizes significant future colocation revenue before the company has demonstrated sustainable free cash flow. A credible contracted capacity pipeline partially supports the premium, but capital intensity and financing requirements limit the current margin of safety.
• Step 8 Summary: Core Scientific offers substantial long-term infrastructure growth potential, yet its current valuation depends heavily on successful capacity commissioning and eventual conversion of contracted revenue into cash returns for equity holders.

💀 Step 9: What Are the Risks of Core Scientific? Fatal Risks & Pre-Mortem

Q9-A1. Is Core Scientific Burning Cash & Diluting Shareholders?

• Cash Consumption: Conventional TTM free cash flow was approximately -$957.75M through June 2026, largely reflecting approximately $1.48B of capital expenditures.
• Liquidity Position: Cash and equivalents at June 30, 2026 were approximately $1.77B, while reported total debt was approximately $4.41B, leaving approximately $2.64B of net debt.
• Funding Exposure: The company obtained an additional $600M of senior secured facilities in August 2026. This improves funding availability but also introduces further borrowing obligations and potential restrictions.
• Runway Interpretation: A simple cash-divided-by-FCF calculation is not a reliable survival estimate because capital spending is project-specific, customer funding matters, and available borrowing facilities can alter liquidity.
• Shareholder Dilution: Reported outstanding shares increased approximately 3.62% YoY. This does not establish excessive annual dilution, but future equity issuance remains a possible source of funding.
• Key Risk Conclusion: Persistent negative construction-phase free cash flow and substantial debt create a continuing financing requirement even as the operating colocation business grows rapidly.

Q9-A2. Do Competition or Regulation Threaten Core Scientific?

• Infrastructure Competition: Competing AI data-center developers can secure alternative powered sites, customer commitments, and financing, potentially reducing Core Scientific’s ability to obtain premium contract economics.
• Customer Concentration: Dependence on a relatively limited number of large counterparties creates operational and credit exposure if a customer delays deployment, modifies requirements, or experiences financial stress.
• Utility and Regulatory Constraints: Interconnection approvals, grid capacity, electricity pricing, environmental permitting, and local development requirements can delay operational capacity.
• Technology Requirements: Continued increases in computing density may require additional cooling and electrical infrastructure investment, raising construction costs and affecting facility returns.
• Competitive Assessment: The threat is principally infrastructure delivery and customer concentration rather than an imminent substitution of the physical colocation service by software.

Q9-A3. Core Scientific Pre-Mortem: What Could Go Wrong?

• 1 Major data-center construction delays: Several large projects miss their commissioning schedules, leaving substantial capital invested without corresponding billable revenue.
  • Early Warning Signal: Billing MW growth materially trails announced development milestones while construction expenditure and interest costs continue rising.
• 2 Financing pressure accelerates: Persistent negative FCF and elevated borrowing requirements reduce funding flexibility, prompting expensive refinancing, asset sales, or equity issuance.
  • Early Warning Signal: Available liquidity declines sharply while debt increases and construction commitments remain high.
• 3 Customer demand or contract economics deteriorate: A major customer reduces deployment commitments or delays facility acceptance, lowering projected revenue and returns on dedicated infrastructure.
  • Early Warning Signal: Contract modifications, delayed customer acceptance, reduced leased capacity, or material customer-related asset impairments appear in company disclosures.

Q9-A4. Risk Adjustment Score

• Reason for Scoring: Core Scientific reported approximately $957.75M of negative TTM conventional FCF, $4.41B of debt, and $2.64B of net debt at June 2026, confirming a substantial continuing exposure to construction financing and project execution. Its $1.77B cash balance, long-term contracted capacity, and additional secured facilities provide meaningful financial mitigants, while the capital program continues to require significant funding.
• 📊 Risk Adjustment Score: -8 pts
• Step 9 Summary: Core Scientific’s largest non-valuation risk is the mismatch between rapid infrastructure construction spending and the timing of recurring customer cash generation. Liquidity and contracted revenue provide resilience, but project delays could materially weaken the financial trajectory.

🎯 Step 10: Core Scientific Final Verdict: Score & Rating

Q10-A1. Investment Score & Rating

• Investment Score Calculation Formula:
  • Step breakdown: S2 (25) + S3 (22) + S4 (7) + S5 (11) + S6 (3) + S7 (4) = 72 pts
  • Steps 2-7 Sum (72 pts) + Valuation Adjustment (-5 pts) + Risk Adjustment (-8 pts) = Investment Score 59 pts
• Investment Score & Rating: 59 pts (C Rating ⭐⭐)
  • Commentary: Exceptional colocation growth and significant contracted capacity provide the primary fundamental strengths. These advantages are offset by substantial construction expenditures, recurring accounting losses, financing obligations, and a valuation dependent on future operating milestones.

Q10-A2. Should You Buy Core Scientific? (Recommendation)

• Recommendation: Sell
  • Commentary: Core Scientific has established a credible AI infrastructure growth platform, but the capital required to realize its contracted capacity remains substantial relative to current operating cash generation. The combination of aggressive development spending, financing exposure, and demanding valuation reduces the attractiveness of the present risk-reward balance.

Q10-A3. Investment Thesis in One Line

• Core Scientific could become a major contracted AI data-center infrastructure provider through rapid power-capacity activation, but heavy construction spending, debt, and uncertain free cash flow threaten equity returns.

Q10-A4. Core Scientific’s Price Trend & Key Drivers

• Stock Price Trend Over the Past 12 Months: Volatile Decline 📉 — CORZ closed at $13.25 on October 30, 2026, substantially below its 52-week high of $30.46 and near its 52-week low of $12.31. The stock has experienced sharp revaluations as investors reassessed AI infrastructure growth, financing requirements, and development execution.
• October 30, 2025 Termination of the CoreWeave Acquisition
  • Description: Core Scientific shareholders rejected the proposed all-stock acquisition, preserving CORZ as an independently traded company and restoring direct exposure to the company’s standalone development strategy.
  • Stock Price Reaction: Mixed Trading ➡️ — Early trading coverage described an initial decline before shares stabilized later in the session, reflecting competing interpretations of the failed merger and standalone growth potential.
• July 28, 2026 AMD Partnership and Second-Quarter Results
  • Description: The company announced a substantial AMD infrastructure partnership while reporting rapidly expanding colocation revenue and billable capacity.
  • Stock Price Reaction: Direction Not Reliably Established — A consistent event-window trading record was not established to separate the announcement response from broader AI infrastructure market movements.
• October 30, 2026 Renewed Sector-Wide Selling Pressure
  • Description: Investors reassessed the debt and capital intensity of rapidly expanding AI infrastructure developers ahead of Core Scientific’s next earnings release.
  • Stock Price Reaction: Sharp Decline 📉 — CORZ fell 8.18% during the October 30 session, declining from $14.43 to $13.25.

Q10-A5. Action Plan

• ⚠️ Since the Investment Score for the analyzed company is 59 pts and the Recommendation falls under Sell, this Action Plan section is omitted as the stock is not suitable for investment.

🕵️‍♂️ Deep Dive Analysis

• ⚠️ Since the Investment Score for the analyzed company is 59 pts and the Recommendation falls under Sell, this Deep Dive section is omitted as the stock is not suitable for investment.